 |
0 Diseases |  |
2 Trials |
|
2 Trials |  |
16 News |  |
- || AMG 224 / Amgen
Trial completion, Trial completion date: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 18, 2022
P1, N=42, Completed, Sponsor: Amgen
Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Apr 2022
- || AMG 224 / Amgen
Clinical, P1 data, Journal: Letter phase 1 study of the anti-BCMA antibody-drug conjugate AMG 224 in patients with relapsed/refractory multiple myeloma. (Pubmed Central) - Jan 14, 2021
Active, not recruiting --> Completed | Trial completion date: Sep 2023 --> Apr 2022 No abstract available
- | AMG 224 / Amgen
Trial completion date: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 2, 2020
P1, N=41, Active, not recruiting, Sponsor: Amgen
No abstract available Trial completion date: Mar 2022 --> Sep 2023
- | AMG 224 / Amgen
Moooorning, dearest Biiotwitter Because we always go back to our first love♥ $AMGN Ph1 study of AMG-224 (aBCMA) in R/R MM n=42 ORR: 23% mDoR: 14.7m https://t.co/VJAY3ZeNkn (Twitter) - Apr 27, 2020
- || AMG 224 / Amgen, belantamab mafodotin (GSK2857916) / GSK
Belantamab: after median F/U of 6.3 to 6.9 months, median duration of response not reached. AMG224: In dose escalation cohort, the median duraation of response was 14.7 (4.1 - 29.8) months (Twitter) - Apr 26, 2020
- ||||| AMG 224 / Amgen
Clinical, Adverse events: Conclusion of now published two BCMA ADC trial - GSK916= BelaMaf and AMG224 - efficacy of single agent is ~30% - side effect is dictated by war-head used. - MMAF and DM1 both have thrombocytopenia and ocular toxicity #mmsm @NoopurRajeMD @DrOlaLandgren Hans Lee @MDAndersonNews (Twitter) - Apr 26, 2020
- | AMG 224 / Amgen
Trial completion date: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 11, 2019
P1, N=41, Active, not recruiting, Sponsor: Amgen
Trial completion date: Mar 2022 --> Sep 2023 Trial completion date: May 2020 --> Mar 2022
- | AMG 224 / Amgen
Trial completion date, Trial primary completion date: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Oct 18, 2018
P1, N=41, Active, not recruiting, Sponsor: Amgen
Trial completion date: May 2020 --> Mar 2022 Trial completion date: Sep 2020 --> May 2020 | Trial primary completion date: Sep 2020 --> Dec 2018
- || AMG 224 / Amgen
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 20, 2018
P1, N=41, Active, not recruiting, Sponsor: Amgen
Trial completion date: Sep 2020 --> May 2020 | Trial primary completion date: Sep 2020 --> Dec 2018 Recruiting --> Active, not recruiting | N=60 --> 41 | Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2020
- || AMG 224 / Amgen
Enrollment change, Trial primary completion date: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Jun 26, 2017
P1, N=60, Recruiting, Sponsor: Amgen
Recruiting --> Active, not recruiting | N=60 --> 41 | Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Sep 2018 --> Sep 2020 N=50 --> 60 | Trial primary completion date: May 2018 --> Aug 2018
- AMG 224 / Amgen
Trial primary completion date: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Apr 27, 2016
P1, N=50, Recruiting, Sponsor: Amgen
N=50 --> 60 | Trial primary completion date: May 2018 --> Aug 2018 Trial primary completion date: Mar 2020 --> May 2018
- AMG 224 / Amgen
Trial primary completion date: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Mar 23, 2016
P1, N=50, Recruiting, Sponsor: Amgen
Trial primary completion date: Mar 2020 --> May 2018 Trial primary completion date: May 2017 --> Mar 2020
- AMG 224 / Amgen
Enrollment open: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Dec 5, 2015
P1, N=50, Recruiting, Sponsor: Amgen
Trial primary completion date: May 2017 --> Mar 2020 Not yet recruiting --> Recruiting
- | AMG 224 / Amgen
New P1 trial: A Phase 1 Study in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 28, 2015
P1, N=50, Not yet recruiting, Sponsor: Amgen
- | AMG 224 / Amgen
New P1 trial: A Phase 1 First in Human Study of AMG 224 in Subjects With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Sep 3, 2015
P1, N=50, Not yet recruiting, Sponsor: Amgen